Short- and Long-Term Impact of Prior Chronic Obstructive Pulmonary Disease Exacerbations on Healthcare Resource Utilization and Related Costs: An Observational Study (SHERLOCK)

References

• GBD Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet Respir Med. 2020;8(6):585–596.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease report 2021. [cited Apr 5 2021]. Available from: https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf.
   Google Scholar
• Kim V, Aaron SD. What is a COPD exacerbation? Current definitions, pitfalls, challenges and opportunities for improvement. Eur Respir J. 2018;52(5):1801261. DOI:10.1183/13993003.01261-2018
   PubMed Web of Science ®Google Scholar
• Hurst JR, Skolnik N, Hansen GJ, et al. Understanding the impact of chronic obstructive pulmonary disease exacerbations on patient health and quality of life. Eur J Intern Med. 2020;73:1–6. DOI:10.1016/j.ejim.2019.12.014
   PubMed Web of Science ®Google Scholar
• Thomas M, Radwan A, Stonham C, et al. COPD exacerbation frequency, pharmacotherapy and resource use: an observational study in UK primary care. COPD. 2014;11(3):300–309. DOI:10.3109/15412555.2013.841671
   PubMedGoogle Scholar
• Müllerová H, Shukla A, Hawkins A, et al. Risk factors for acute exacerbations of COPD in a primary care population: a retrospective observational cohort study. BMJ Open. 2014;4(12):e006171. DOI:10.1136/bmjopen-2014-006171
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Law M, Kowlessar B, et al. Impact of prolonged exacerbation recovery in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192(8):943–950. DOI:10.1164/rccm.201412-2269OC
   PubMed Web of Science ®Google Scholar
• Rothnie KJ, Müllerová H, Smeeth L, et al. Natural history of chronic obstructive pulmonary disease exacerbations in a general practice-based population with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198(4):464–471. DOI:10.1164/rccm.201710-2029OC
   PubMed Web of Science ®Google Scholar
• Johansson G, Mushnikov V, Bäckstrom T, et al. Exacerbations and healthcare resource utilization among COPD patients in a swedish registry-based nation-wide study. BMC Pulm Med. 2018;18(1):17. DOI:10.1186/s12890-018-0573-0
   PubMedGoogle Scholar
• Chetty M, MacKenzie M, Douglas G, et al. Immediate and early discharge for patients with exacerbations of chronic obstructive pulmonary disease: is there a role in “real life”? Int J Chron Obstruct Pulmon Dis. 2006;1(4):401–407. DOI:10.2147/copd.2006.1.4.401
   PubMedGoogle Scholar
• Punekar YS, Shukla A, Müllerova H. COPD management costs according to the frequency of COPD exacerbations in UK primary care. Int J Chron Obstruct Pulmon Dis. 2014;9(1):65–73. DOI:10.2147/COPD.S54417
   PubMed Web of Science ®Google Scholar
• Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932–946. DOI:10.1183/09031936.04.00014304
   PubMed Web of Science ®Google Scholar
• European Respiratory Society. European Lung White Book. 2013. https://www.erswhitebook.org/.
   Google Scholar
• Guarascio AJ, Ray SM, Finch CK, et al. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res. 2013 2013;5:235–245.
   PubMedGoogle Scholar
• Mapel DW, Schum M, Lydick E, et al. A new method for examining the cost savings of reducing COPD exacerbations. Pharmacoeconomics. 2010;28(9):733–749.
   PubMed Web of Science ®Google Scholar
• Haughney J, Lee AJ, Nath M, et al. The long-term clinical impact of COPD exacerbations: a 3-year observational study (SHERLOCK). Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666211070139. DOI:10.1177/17534666211070139
   Web of Science ®Google Scholar
• NHS Greater Glasgow and Clyde. Glasgow Safe Haven User Guide. 2021 [cited 2021 Apr 5]. https://www.nhsggc.org.uk/about-us/professional-support-sites/glasgow-safe-haven/.
   Google Scholar
• Vestbo J, Leather D, Diar Bakerly N, Salford Lung Study Investigators, et al. Effectiveness of fluticasone furoate–vilanterol for COPD in clinical practice. N Engl J Med. 2016;375(13):1253–1260. DOI:10.1056/NEJMoa1608033
   PubMed Web of Science ®Google Scholar
• De Nigris E, Holmgren U, Aurivillius M, et al. The cost of a severe COPD exacerbation, estimated from recent triple therapy studies in patients with COPD: KRONOS and ETHOS [abstract]. Am J Respir Crit Care Med. 2020;201(A6290). DOI:10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A6290
   Google Scholar
• Blasi F, Cesana G, Conti S, et al. The clinical and economic impact of exacerbations of chronic obstructive pulmonary disease: a cohort of hospitalized patients. PLoS One. 2014;9(6):e101228. DOI:10.1371/journal.pone.0101228
   PubMed Web of Science ®Google Scholar
• Pasquale MK, Sun SX, Song F, et al. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly medicare population. Int J Chron Obstruct Pulmon Dis. 2012 2012;7:757–764.
   PubMed Web of Science ®Google Scholar
• Kerkhof M, Freeman D, Jones R, et al. Predicting frequent COPD exacerbations using primary care data. Int J Chron Obstruct Pulmon Dis. 2015;10:2439–2450.
   PubMed Web of Science ®Google Scholar
• Husebø GR, Bakke PS, Aanerud M, et al. Predictors of exacerbations in chronic obstructive pulmonary disease - results from the bergen COPD cohort study. PLoS One. 2014;9(10):e109721. DOI:10.1371/journal.pone.0109721
   PubMed Web of Science ®Google Scholar
• Kostikas K, Price D, Gutzwiller FS, et al. Clinical impact and healthcare resource utilization associated with early versus late COPD diagnosis in patients from UK CPRD database. Int J Chron Obstruct Pulmon Dis. 2020;15:1729–1738. DOI:10.2147/COPD.S255414
   PubMed Web of Science ®Google Scholar
• Wallace AE, Kaila S, Bayer V, et al. Health care resource utilization and exacerbation rates in patients with COPD stratified by disease severity in a commercially insured population. J Manag Care Spec Pharm. 2019;25(2):205–217. DOI:10.18553/jmcp.2019.25.2.205
   PubMed Web of Science ®Google Scholar
• Kim Y, Kim K, Rhee CK, et al. Increased hospitalizations and economic burden in COPD with bronchiectasis: a nationwide representative study. Sci Rep. 2022;12(1):3829. DOI:10.1038/s41598-022-07772-6
   PubMed Web of Science ®Google Scholar
• Dhamane AD, Moretz C, Zhou Y, et al. COPD exacerbation frequency and its association with health care resource utilization and costs. Int J Chron Obstruct Pulmon Dis. 2015;10:2609–2618. DOI:10.2147/COPD.S90148
   PubMed Web of Science ®Google Scholar
• DeTora LM,Toroser D,Sykes A,et al.Good Publication Practice (GPP) guidelines for company-sponsored biomedical research: 2022 update. Ann Intern Med. 2022;175(9):1298–1304. DOI:10.7326/M22-1460
   Google Scholar